Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German urologists develop online prostate biopsy tool:

This article was originally published in Clinica

Executive Summary

Urologists at Berlin's Charite Hospital have developed a computer programme aimed at determining whether a biopsy is necessary in the event of elevated PSA values. The programme, called "Risk estimation for prostate cancer", was devised on the basis of results from 944 patients who visited the hospital between 1996-2001. Free and total PSA values, as well as the patient's age, prostate volume and results of digital rectal examinations are fed into the programme. Additionally, doctors can include specificity and sensitivity values to determine the necessity of biopsy. The programme, which was developed by Carsten Stephan and Henning Cammann, does not yet recognise PSA values recorded when using the test system developed by Los Angeles, California-based firm Immulite, however the system may be adapted to cover these in the future. It can be accessed via the internet at: http://www.charite.de/ch/uro/schwerpunkte/pclass.html

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063891

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel